RUFY2 is altered in 0.04% of all cancers with lung adenocarcinoma, breast invasive ductal carcinoma, thyroid gland papillary carcinoma, adenocarcinoma of unknown primary, and bladder urothelial carcinoma having the greatest prevalence of alterations .
The most common alteration in RUFY2 is RUFY2-RET Fusion (0.04%) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.